Delving into the Latest Updates on Zonhon Biopharma Institute, Inc. with Synapse

Overview

Basic Info

Introduction

Zonhon Biopharma Institute, Inc. is dedicated to the research, development, and commercialization of innovative drugs, including proprietary gene-engineered recombinant enzymes for cardiovascular and cerebrovascular diseases, cancer, diabetes, and respiratory illnesses; human and humanized antibodies targeting new markers; allergen desensitization products; long-acting modified proteins; and peptides. Additionally, the company focuses on the development and application of clinical diagnostic reagents and new biomaterials for biomedicine.

Tags

Cardiovascular Diseases

Immune System Diseases

Neoplasms

Biological products

Allergen extract

Recombinant polypeptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Immune System Diseases	6
Nervous System Diseases	5
Infectious Diseases	3

Top 5 Drug Type	Count

Biological products	16
Unknown	3
Allergen extract	3
Recombinant polypeptide	1

Top 5 Target	Count

IL-2(Interleukin-2)	1

The primary objective is to evaluate the tolerability and safety of single and multiple doses of QHRD106 injection in healthy Chinese subjects, and provide a basis for subsequent clinical trials. The secondary objective is to evaluate the pharmacokinetic characteristics of QHRD106 injection in healthy Chinese subjects.

Start Date10 Mar 2023

Sponsor / Collaborator

Zonhon Biopharma Institute, Inc.

[+1]

100 Clinical Results associated with Zonhon Biopharma Institute, Inc.

Login to view more data

0 Patents (Medical) associated with Zonhon Biopharma Institute, Inc.

Login to view more data

3

Literatures (Medical) associated with Zonhon Biopharma Institute, Inc.

01 Jun 2024·Phytomedicine

Yi-Qi-Huo-Xue decoction alleviates intracerebral hemorrhage injury through inhibiting neuronal autophagy of ipsilateral cortex via BDNF/TrkB pathway

Article

Author: Yang, Zhaocong ; Xu, Dan ; Wang, Siliang ; Chang, Xinyue ; Wang, Meihua ; Han, Dan ; Shen, Jizhong ; Fan, Ali ; Li, Dingran ; Wang, Cheng ; Wu, Yi ; Li, Jian ; Chen, Xiangkai

BACKGROUNDYi-Qi-Huo-Xue Decoction (YQHXD), a traditional Chinese medicine formula, has demonstrated efficacy in the clinical treatment of intracerebral hemorrhage (ICH) for over a decade. Nevertheless, the precise pharmacotherapeutic compounds of YQHXD capable of penetrating into cerebral tissue and the pharmacological underpinnings of YQHXD remain ambiguous.METHODSThe active components of YQHXD in rat brains was analyzed by ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. The potential targets, pathways and biological progresses of YQHXD ameliorating ICH induced injury was predicted by network pharmacology. Moreover, collagenase-induced ICH rat model, primary cortex neurons exposed to hemin and molecular docking were applied to validate the molecular mechanisms of YQHXD.RESULTSEleven active components of YQHXD were identified within the brains. Employing the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases, our investigation concentrated on the roles of autophagy and the BDNF/TrkB signaling pathway in the pharmacological context. The pharmacological results revealed that YQHXD alleviated neurological dysfunction, brain water content, brain swelling, and pathological injury caused by ICH. Meanwhile, YQHXD inhibited autophagy influx and autophagosome in vivo, and regulated cortex neuronal autophagy and TrkB/BDNF pathway both in vivo and in vitro. Subsequently, N-acetyl serotonin (NAS), a selective TrkB agonist, was employed to corroborate the significance of the BDNF/TrkB pathway in this process. The combination of NAS and YQHXD did not further enhance the protective efficacy of YQHXD in ICH rats. Additionally, outcomes of molecular docking analysis revealed that nine compounds of YQHXD exhibited potential regulatory effects on TrkB.CONCLUSIONSIpsilateral neuronal autophagy and BDNF/TrkB pathway were activated 72 h after ICH. YQHXD effectively resisted injury induced by ICH, which was related with suppression of ipsilateral neuronal autophagy via BDNF/TrkB pathway. This study provides novel insights into the therapeutic mechanisms of traditional Chinese medicine in the context of ICH treatment.

01 Feb 2014·The Journal of ImmunologyQ2 · MEDICINE

Mannan-Binding Protein, a C-Type Serum Lectin, Recognizes Primary Colorectal Carcinomas through Tumor-Associated Lewis Glycans

Q2 · MEDICINE

Article

Author: Tani, Tohru ; Nonaka, Motohiro ; Saito, Yasuharu ; Kawasaki, Nobuko ; Imaeda, Hirotsugu ; Matsumoto, Shogo ; Andoh, Akira ; Mekata, Eiji ; Yong Ma, Bruce ; Fujiyama, Yoshihide ; Kawasaki, Toshisuke

AbstractMannan (mannose)-binding protein (MBP) is a C-type serum lectin that plays a key role in innate immunity. MBP forms large multimers (200–600 kDa) and exhibits broad specificity for mannose, N-acetylglucosamine, and fucose. MBP exhibits high affinity for unique oligosaccharides that have been isolated from human colorectal carcinoma (SW1116) cells and characterized as highly fucosylated high m.w. type 1 Lewis glycans. In this study, we first demonstrated that MBP recognizes human primary colorectal carcinoma tissues through tumor-associated MBP ligands. We performed fluorescence-based histochemistry of MBP in human colorectal carcinoma tissues and showed that MBP clearly stained cancer mucosae in a Ca2+-dependent manner. Coincubation with plant (Aleuria aurantia) lectin, but not Con A, blocked MBP staining, indicating that fucose, rather than mannose, is involved in this interaction. The expression of MBP ligands was detected in 127 of 330 patients (38.5%), whereas, most significantly, there was no expression in 69 nonmalignant tissues. The MBP-staining pattern in cancer mucosae significantly overlapped with that of Lewis b [Fucα1-2Galβ1-3(Fucα1-4)GlcNAc] staining, but the Lewis b staining in normal tissues was not associated with MBP staining. In addition, the MBP staining correlated inversely with the expression of CA19-9 Ag, and MBP stained 11 of 25 (44%) CA19-9 (sialyl Lewis a [NeuAc(α2-3)Galβ1-3(Fucα1-4)GlcNAc])− colorectal carcinoma tissues. We found a favorable prognosis in patients with MBP ligand+ tumors. These results suggest that selective recognition of cancer cells by endogenous MBP seems to be associated with an antitumor effect and that tissue staining with MBP in combination with CA19-9 may serve as a novel indicator of colorectal carcinoma tissues.

Applied Sciences

Glycan-Dependent and -Independent Dual Recognition between DC-SIGN and Type II Serine Protease MSPL/TMPRSS13 in Colorectal Cancer Cells

Author: Kido, Hiroshi ; Nonaka, Motohiro ; Kawasaki, Nana ; Matsumoto, Shogo ; Ma, Bruce Yong ; Kawasaki, Toshisuke ; Kawasaki, Nobuko

A class of glycoproteins such as carcinoembryonic antigen (CEA)/CEA-related cell adhesion molecule 1(CEACAM1), CD26 (DPPIV), and mac-2 binding protein (Mac-2BP) harbor tumor-associated glycans in colorectal cancer. In this study, we identified type II transmembrane mosaic serine protease large-form (MSPL) and its splice variant transmembrane protease serine 13 (TMPRSS13) as ligands of Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) on the colorectal cancer cells. DC-SIGN is a C-type lectin expressed on dendritic cells, serves as a pattern recognition receptor for numerous pathogens such as human immunodeficiency virus (HIV) and M. tuberculosis. DC-SIGN recognizes these glycoproteins in a Ca2+ dependent manner. Meanwhile, we found that MSPL proteolytically cleaves DC-SIGN in addition to the above glycan-mediated recognition. DC-SIGN was degraded more efficiently by MSPL when treated with ethylenediaminetetraacetic acid (EDTA), suggesting that glycan-dependent interaction of the two molecules partially blocked DC-SIGN degradation. Our findings uncovered a dual recognition system between DC-SIGN and MSPL/TMPRSS13, providing new insight into the mechanism underlying colorectal tumor microenvironment.

100 Deals associated with Zonhon Biopharma Institute, Inc.

Login to view more data

100 Translational Medicine associated with Zonhon Biopharma Institute, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

16

Preclinical

IND Application

2

4

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ZHB-A002	Rhinitis, Allergic More	Phase 1
ZHB103	Ischemic stroke More	Phase 1
ZHB107-108	Allergic asthma More	Phase 1
ZHB-C002	Solid tumor More	Phase 1
ZHB-N002	Ischemic stroke More	IND Application